ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD) a clinical-stage BioPharma firm developing medication candidates to cure Alzheimer’s disease, pain, CNS diseases, and cancers, reported that it will present full PART A data and initial PART B results from the underway Phase 2a clinical study of ANAVEX 2-73 at the Clinical Trials on Alzheimer’s Disease conference to be held in Barcelona from November 5 to November 7, 2015. The company reported that the late-breaking oral lecture will be presented by the study’s Principal Investigator, Mr. Stephen Macfarlane, FRANZCP, Associate Professor and Director, Aged Psychiatry at Caulfield Hospital in Australia.

The details

The multicenter Phase IIa clinical study of ANAVEX 2-73 comprises of two distinct parts and a total of thirty-two subjects suffering from mild-to-moderate Alzheimer’s. Anavex stated that PART A is a simple randomized, two-period, cross-over, open-label, adaptive study lasting up to thirty-six days for each subject. On the other hand PART B of Phase 11a clinical study is an open-label extension lasting for an additional fifty-two weeks.

Study objectives

The primary goal of the study is to determine the maximum tolerated dose of experimental medication ANAVEX 2-73. Anavex reported that secondary trial goals include exploratory cognitive efficiency using MMSE, dose response, Cogstate and electroencephalographic activity, including EEG/ERP and bioavailability, as well as the relationship of lead drug ANAVEX 2-73 as an add-on medication to donepezil. Additional information pertaining to the underway Phase 2a clinical study can be accessed on the site of the U.S. National Institutes of Health clinical studies database.


It is an investigational therapy in the Phase 2a study and is Anavex’s lead investigational cure for fatal Alzheimer’s disease. It target areas are sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding, tau, inflammation and beta amyloid. Preclinical results suggest that experimental drug has the potential to halt, reverse or prevent the course of Alzheimer’s disease.

Previous articleVolkswagen AG (ADR)(OTCMKTS:VLKAY) Emissions Retrofit Can Turn Out Costliest Fixes In Automotive Industry
Next articleWhy Nestle SA Reg Shs. Ser. B Spons (ADR)(OTCMKTS:NSRGY) Lowered Full-Year Guidance?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.